DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
H•••• T••••••••• I••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor unattributed
Also written as: 2015; 2023; 25; 7; 7/25/2015; 7/25/2023; Equity; Inc. and
Principal held
at least $80.8M
sum of BDC pieces, a lower bound
Fair value
$78.7M
97c on cost, debt pieces
Unfunded
n/a
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
3 equity pieces beside them
Next maturity
Sep 1, 2030
no dated debt inside 24 months
On the tape since
Sep 30, 2023
latest Jun 30, 2026
Events
2
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $80.8M | 97c | S+195 bp PIK 1.00% | Sep 1, 2030 | 1 |
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien Senior Secured, September 2030, Prime + 1.95%, Floor rate 9.45%, PIK Interest 1.00%, 6.50% | $80.8M | $78.5M 97c | S+195 bp PIK 1.00% |
| H••••••• C••••••• I••• | warrants equity Warrant, 8/9/2023, Common Stock | n/a | $4,000 2c | |
| H••••••• C••••••• I••• | equity equity Common Stock | n/a | $156,000 31c |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $80.8M | $78.5M | 97c | 1 |
| Mar 31, 2026 | 1 | $80.6M | $79.2M | 99c | 1 |
| Dec 31, 2025 | 1 | $161M | $160M | 100c | 2 |
| Sep 30, 2025 | 1 | $80.2M | $79.5M | 100c | 1 |
| Jun 30, 2025 | 1 | $20.6M | $21.6M | 104c | 1 |
| Mar 31, 2025 | 1 | $20.5M | $20.7M | 100c | 1 |
| Dec 31, 2024 | 1 | $40.8M | $42.0M | 103c | 2 |
| Sep 30, 2024 | 1 | $20.3M | $20.8M | 102c | 1 |
| Jun 30, 2024 | 1 | $20.2M | $20.6M | 102c | 1 |
| Mar 31, 2024 | 1 | $20.2M | $20.4M | 102c | 1 |
| Dec 31, 2023 | 1 | $60.3M | $59.4M | 100c | 3 |
| Sep 30, 2023 | 1 | $20.0M | $19.6M | 100c | 1 |
What changed
- Maturity extended (observed)Sep 30, 2025
- Maturity extended (observed)Sep 30, 2025
- New borrower on a BDC scheduleSep 30, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- H•••• T•••••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it